Randomized placebo-controlled trial of emricasan for non-alcoholic steatohepatitis-related cirrhosis with severe portal hypertension

Medicine & Life Sciences

• 3-(2-(2-tert-butylphenylaminooxalyl)aminopropionylamino)-4-oxo-5-(2,3,5,6-tetrafluorophenoxy)pentanoic acid 100%
• Venous Pressure 54%
• Portal Hypertension 53%
• Fatty Liver 52%
• Fibrosis 36%
• Placebos 33%
• Randomized Controlled Trials 32%
• Liver 25%
• Portal Pressure 16%
• Biomarkers 7%
• Liver Cirrhosis 7%
• Cicatrix 7%
• Clinical Trials 5%
• Caspase Inhibitors 4%
• End Stage Liver Disease 4%
• Transaminases 4%
• Keratins 4%
• Portal Vein 4%
• Caspases 4%
• Double-Blind Method 3%
• Therapeutics 3%
• Pressure 2%
• Inflammation 2%
• Child 1%
• Pharmaceutical Preparations 1%